Last week FDA announced that they have set a date for its first public hearing on rulemaking for CBD products. Set your calendars for May 31st!
This first hearing will inform FDAs process on rulemaking and will feature plenty of testimony from stakeholders with an interest in rules surrounding CBD. But as outgoing commissioner Scott Gottlieb has said in the past, the rulemaking process could potentially take years without Congressional intervention because CBD is such a novel substance.
Because CBD is an FDA-approved drug in the form of prescription medication Epidiolex and hasn’t been previously introduced into the food supply, regulating CBD products is especially complicated, Gottlieb has said. However, there are alternative pathways the agency can pursue, and the public hearing is one of the first steps in that rulemaking process.
“The goal of the hearing is to obtain additional scientific data and other information related to cannabis and cannabis-derived compounds, both from botanical and synthetic sources, to inform our regulatory oversight of these products,” the agency wrote. “FDA does not intend for this hearing to produce any decisions or new positions on specific regulatory questions, but this hearing is expected to be an important step in our continued evaluation of cannabis and cannabis-derived compounds in FDA-regulated products.”
(Quote: Marijuana Moment)
FDA will continue to provide regular updates on their website. Those who are interested can find the site here. If you'd like to read the entire announcement from Scott Gottlieb, and it's worth the read, it can be found here.
And of course, stay tuned to Glo for more information. We will be keeping up up-to-date and submitting our comments as the process moves forward.